

### **Takeda to win EU approval for USD 62 bln Shire deal**

Japanese drugmaker Takeda Pharmaceutical is set to win conditional EU antitrust approval for its USD 62-billion bid for London's Shire. Last October, Takeda offered to divest Shire Plc's pipeline compound SHP647 along with some associated rights after the European Commission voiced concerns about the overlap with its own drug for inflammatory bowel disease called Entyvio.